Zydus, a leading discovery based, international pharmaceutical employer has introduced that United States Food and Drug Administration (USFDA) has granted ‘Orphan Drug Designation’ (ODD) to Saroglitazar Mg for the treatment of patients with Primary Biliary Cholangitis (PBC). Orphan drug designation presents eligibility for sure development incentives, along with tax credits for qualified medical trying out, prescription drug person charge exemptions and 7-yr advertising and marketing exclusivity upon FDA approval. This follows the provide of ‘Fast Track Designation’ by means of the USFDA to Saroglitazar Mg for PBC in December 2020.